This is therefore a contrasting of the analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation in Pulmatrix Inc. (NASDAQ:PULM) and Affimed N.V. (NASDAQ:AFMD). The two are both Biotechnology companies that compete with one another.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmatrix Inc.	N/A	80.10	20.56M	-6.88	0.00
Affimed N.V.	N/A	0.00	N/A	-0.70	0.00

We can see in table 1 the earnings per share, top-line revenue and valuation of Pulmatrix Inc. and Affimed N.V.

Profitability

Table 2 demonstrates the net margins, return on assets and return on equity of Pulmatrix Inc. and Affimed N.V.

	Net Margins	Return on Equity	Return on Assets
Pulmatrix Inc.	0.00%	-176.2%	-124.7%
Affimed N.V.	0.00%	-82.1%	-63.5%

Volatility and Risk

Pulmatrix Inc. is 66.00% more volatile than Standard and Poor’s 500 due to its 1.66 beta. Affimed N.V. on the other hand, has 3.34 beta which makes it 234.00% more volatile compared to Standard and Poor’s 500.

Liquidity

The Current Ratio and Quick Ratio of Pulmatrix Inc. are 1.3 and 1.3 respectively. Its competitor Affimed N.V.’s Current Ratio is 3.7 and its Quick Ratio is 3.6. Affimed N.V. can pay off short and long-term obligations better than Pulmatrix Inc.

Analyst Recommendations

In next table is given Pulmatrix Inc. and Affimed N.V.’s ratings and recommendations.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Pulmatrix Inc.	0	0	0	0.00
Affimed N.V.	0	0	1	3.00

Competitively the average price target of Affimed N.V. is $8, which is potential 108.33% upside.

Insider and Institutional Ownership

Institutional investors owned 12.7% of Pulmatrix Inc. shares and 41.9% of Affimed N.V. shares. About 7.53% of Pulmatrix Inc.’s share are owned by insiders. Competitively, Affimed N.V. has 12.63% of it’s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Pulmatrix Inc.	17.55%	-8.59%	-68.97%	-71.95%	-91.7%	-51.27%
Affimed N.V.	5.8%	6.41%	-18.34%	-40.65%	56.99%	17.36%

For the past year Pulmatrix Inc. has -51.27% weaker performance while Affimed N.V. has 17.36% stronger performance.

Summary

Affimed N.V. beats Pulmatrix Inc. on 7 of the 8 factors.

Pulmatrix, Inc., a clinical stage biopharmaceutical company, engages in developing inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. The companyÂ’s proprietary product pipeline focuses on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis, as well as PUR1500, an inhaled product for the treatment of idiopathic pulmonary fibrosis (IPF). It is also developing PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease. The company has an alliance with Celdara to develop an inhaled biologic to treat IPF. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The companyÂ’s product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its product candidates also comprise AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia; and AMV564, a CD33/CD3-specific T-cell TandAb for the treatment of acute myeloid leukemia and other hematologic malignancies. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD AndersonÂ’s NK-cell product. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.